Each quarter the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are conducted free of charge for Awardees.
This quarter’s awardees are Prof. Zheng-Rong Lu, Case Western Reserve University; Prof. Jordan Green, Johns Hopkins University; and BioSynectics, Inc. Please click here to download a pdf of the announcement.
If you’re interested in applying for next quarter, please download our White Paper application here: https://ncl.cancer.gov/working-ncl/ncl-assay-cascade-application-process. The next deadline in December 1, 2018. If you have any questions about the process, please feel free to contact us at firstname.lastname@example.org.